Literature DB >> 9249239

Differential contribution of two serine residues of wild type and constitutively active beta2-adrenoceptors to the interaction with beta2-selective agonists.

H Kikkawa1, H Kurose, M Isogaya, Y Sato, T Nagao.   

Abstract

1. We have studied the difference in receptor binding activity between partial and full beta2-adrenoceptor agonists and the abilities of the agonists to interact with Ser204 and Ser207 in the fifth transmembrane region of the beta2-adrenoceptor, amino acid residues that are important for activation of the beta2-adrenoceptor. 2. In the binding study with [125I]-iodocyanopindolol, the Ki values of (+/-)-salbutamol, (+/-)-salmeterol, TA-2005 and (-)-isoprenaline for the beta2-adrenoceptor expressed in COS-7 cell membranes were 3340, 21.0, 12.0 and 904 nM, respectively. The beta1/beta2 selectivity of these agonists was in the order of (+/-)-salmeterol (332 fold) > TA-2005 (52.8) > (+/-)-salbutamol (6.8) > (-)-isoprenaline (1.1), and the beta3-/beta2-adrenoceptor selectivity of these agonists was in the order of TA-2005 (150 fold) > (+/-)-salmeterol (88.6) > (+/-)-salbutamol (10.4) > (-)-isoprenaline (3.2). 3. The maximal activation of adenylyl cyclase by stimulation of the beta1-, beta2- and beta3-adrenoceptors by TA-2005 was 32, 100 and 100% of that by (-)-isoprenaline, respectively, indicating that TA-2005 is a full agonist at the beta2- and beta3-adrenoceptors and a partial agonist at the beta1-adrenoceptor. (+/-)-Salbutamol and (+/-)-salmeterol were partial agonists at both beta1- (8% and 9% of (-)-isoprenaline) and beta2- (83% and 74% of (-)-isoprenaline) adrenoceptors. 4. The affinities of full agonists, TA-2005 and (-)-isoprenaline, were markedly decreased by substitution of Ala for Ser204 (S204A) of the beta2-adrenoceptor, whereas this substitution slightly reduced the affinities of partial agonists, (+/-)-salbutamol and (+/-)-salmeterol. Although the affinities of full agonists for the S207A-beta2-adrenoceptor were decreased, those of partial agonists for the S207A-beta2-adrenoceptor were essentially the same as for the wild type receptor. 5. The constitutively active mutant (L266S, L272A) of the beta2-adrenoceptor had an increased affinity for all four agonists. The affinities of full agonists were decreased by substitution of Ser204 of the constitutively active mutant, whereas the degree of decrease was smaller than that caused by the substitution of the wild type receptor. Although the affinities of (+/-)-salbutamol and (+/-)-salmeterol for the S207A-beta2-adrenoceptor were essentially the same as those for the wild type beta2-adrenoceptor, the affinities of (+/-)-salbutamol and (+/-)-salmeterol for the constitutively active beta2-adrenoceptor were decreased by substitution of Ser207. 6. These results suggest that Ser204 and Ser207 of the wild type and constitutively active beta2-adrenoceptors differentially interacted with beta2-selective agonists.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9249239      PMCID: PMC1564789          DOI: 10.1038/sj.bjp.0701229

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  7 in total

1.  Comparison of dynamics of extracellular accesses to the β(1) and β(2) adrenoceptors binding sites uncovers the potential of kinetic basis of antagonist selectivity.

Authors:  Balaji Selvam; Jeff Wereszczynski; Irina G Tikhonova
Journal:  Chem Biol Drug Des       Date:  2012-05-02       Impact factor: 2.817

2.  Ser203 as well as Ser204 and Ser207 in fifth transmembrane domain of the human beta2-adrenoceptor contributes to agonist binding and receptor activation.

Authors:  T Sato; H Kobayashi; T Nagao; H Kurose
Journal:  Br J Pharmacol       Date:  1999-09       Impact factor: 8.739

3.  Tracheal relaxing effects and beta2 adrenoceptor selectivity of S1319, a novel sponge-derived bronchodilator agent, in isolated guinea-pig tissues.

Authors:  H Suzuki; A Ueno; M Takei; K Sindo; T Miura; M Sakakibara; T Higa; H Fukamachi
Journal:  Br J Pharmacol       Date:  1999-10       Impact factor: 8.739

4.  Molecular mechanisms of ligand-receptor interactions in transmembrane domain V of the alpha2A-adrenoceptor.

Authors:  Juha M Peltonen; Tommi Nyrönen; Siegfried Wurster; Marjo Pihlavisto; Anna-Marja Hoffrén; Anne Marjamäki; Henri Xhaard; Liisa Kanerva; Juha-Matti Savola; Mark S Johnson; Mika Scheinin
Journal:  Br J Pharmacol       Date:  2003-08-18       Impact factor: 8.739

5.  Analysis of full and partial agonists binding to beta2-adrenergic receptor suggests a role of transmembrane helix V in agonist-specific conformational changes.

Authors:  Vsevolod Katritch; Kimberly A Reynolds; Vadim Cherezov; Michael A Hanson; Christopher B Roth; Mark Yeager; Ruben Abagyan
Journal:  J Mol Recognit       Date:  2009 Jul-Aug       Impact factor: 2.137

6.  Ligand-stabilized conformational states of human beta(2) adrenergic receptor: insight into G-protein-coupled receptor activation.

Authors:  Supriyo Bhattacharya; Spencer E Hall; Hubert Li; Nagarajan Vaidehi
Journal:  Biophys J       Date:  2007-12-07       Impact factor: 4.033

7.  Influence of agonist intrinsic activity on the desensitisation of beta2-adrenoceptor-mediated responses in mast cells.

Authors:  Anne-Marie Scola; Lee K Chong; Russell Chess-Williams; Peter T Peachell
Journal:  Br J Pharmacol       Date:  2004-08-02       Impact factor: 8.739

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.